688076 诺泰生物
已收盘 08-23 15:00:00
资讯
新帖
简况
华福证券:给予诺泰生物买入评级
证券之星 · 08-23 18:45
华福证券:给予诺泰生物买入评级
最先从减肥药上赚到钱的中国公司出现了
界面 · 08-23 17:17
最先从减肥药上赚到钱的中国公司出现了
国金证券:给予诺泰生物买入评级
证券之星 · 08-23 16:31
国金证券:给予诺泰生物买入评级
信达证券:给予诺泰生物买入评级
证券之星 · 08-23 16:31
信达证券:给予诺泰生物买入评级
信达证券给予诺泰生物买入评级,业绩高增长,“时间+技术”领先优势逐步扩大
每日经济新闻 · 08-23 15:47
信达证券给予诺泰生物买入评级,业绩高增长,“时间+技术”领先优势逐步扩大
诺泰生物08月23日主力资金流入1132万元 连续7日加仓
市场透视 · 08-23 15:18
诺泰生物08月23日主力资金流入1132万元 连续7日加仓
诺泰生物(688076)双轮驱动高景气增长,2024H1业绩增长符合预期
申万宏源 · 08-23 14:16
诺泰生物(688076)双轮驱动高景气增长,2024H1业绩增长符合预期
民生证券:给予诺泰生物买入评级
证券之星 · 08-23 12:19
民生证券:给予诺泰生物买入评级
诺泰生物(688076):国际化BD持续发力 优质产能领先布局
中金公司 · 08-23 11:04
诺泰生物(688076):国际化BD持续发力 优质产能领先布局
中泰证券给予诺泰生物买入评级,业绩超过预告中枢,多项战略合作落地,产能释放加速,持续高增有望延续
每日经济新闻 · 08-23 10:14
中泰证券给予诺泰生物买入评级,业绩超过预告中枢,多项战略合作落地,产能释放加速,持续高增有望延续
民生证券给予诺泰生物推荐评级:新签多个全球重磅原料药项目,十吨级产能加速建设中
每日经济新闻 · 08-23 09:34
民生证券给予诺泰生物推荐评级:新签多个全球重磅原料药项目,十吨级产能加速建设中
诺泰生物:业绩高增,多肽原料药腾飞
新浪财经 · 08-23 09:07
诺泰生物:业绩高增,多肽原料药腾飞
诺泰生物(688076.SH)发布半年度业绩 净利润2.27亿元 大涨442.77% 每10派1元
智通财经 · 08-22 18:05
诺泰生物(688076.SH)发布半年度业绩 净利润2.27亿元 大涨442.77% 每10派1元
诺泰生物:2024年上半年净利润2.27亿 同比增长442.77%
财通社 · 08-22 17:25
诺泰生物:2024年上半年净利润2.27亿 同比增长442.77%
诺泰生物08月21日主力资金流入399万元 连续5日加仓
自选股智能写手 · 08-21
诺泰生物08月21日主力资金流入399万元 连续5日加仓
医疗服务行业盘中拉升,诺泰生物涨1.03%
自选股智能写手 · 08-21
医疗服务行业盘中拉升,诺泰生物涨1.03%
医疗服务行业盘中拉升,诺泰生物涨1.11%
自选股智能写手 · 08-20
医疗服务行业盘中拉升,诺泰生物涨1.11%
诺泰生物08月19日主力资金流入1406万元 连续3日加仓
自选股智能写手 · 08-19
诺泰生物08月19日主力资金流入1406万元 连续3日加仓
诺泰生物(688076)8月16日主力资金净买入1717.41万元
证券之星 · 08-17
诺泰生物(688076)8月16日主力资金净买入1717.41万元
诺泰生物(688076.SH)通过药品GMP符合性检查
智通财经 · 08-16
诺泰生物(688076.SH)通过药品GMP符合性检查
加载更多
公司概况
公司名称:
江苏诺泰澳赛诺生物制药股份有限公司
所属行业:
医药制造业
上市日期:
2021-05-20
主营业务:
江苏诺泰澳赛诺生物制药股份有限公司是一家聚焦多肽药物及小分子化药进行自主研发与定制研发生产相结合的生物医药企业。公司的主要产品为阿托伐他汀钙片、氨氯地平阿托伐他汀钙片、利拉鲁肽、司美格鲁肽、苯甲酸阿格列汀、比伐芦定、依替巴肽、醋酸兰瑞肽、醋酸奥曲肽、磷酸奥司他韦、胸腺法新、GLP-1/GIP/GCG受体多靶点激动剂1类新药、氟维司群。
发行价格:
15.57
{"stockData":{"symbol":"688076","market":"SH","secType":"STK","nameCN":"诺泰生物","latestPrice":61.45,"timestamp":1724396400000,"preClose":62.09,"halted":0,"volume":4572562,"delay":0,"floatShares":220000000,"shares":220000000,"eps":1.5846,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.64,"latestTime":"08-23 15:00:00","open":63.99,"high":63.99,"low":59.8,"amount":281000000,"amplitude":0.0675,"askPrice":61.45,"askSize":45,"bidPrice":61.31,"bidSize":4,"shortable":0,"etf":0,"ttmEps":1.5846,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":62.09,"symbolType":"stock_kcb","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":68.3,"lowLimit":55.88,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":219779814,"pbRate":5.93,"roa":"--","roe":"9.94%","epsLYR":0.76,"committee":-0.619048,"marketValue":13505000000,"floatMarketCap":13505000000,"peRate":38.779503,"changeRate":-0.0103,"turnoverRate":0.0208,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-08-26。","afterMarket":{"amount":12290,"volume":200,"close":61.45,"buyVolume":0,"sellVolume":0,"time":1724398437153,"indexStatus":"已收盘 08-23 15:30:00","preClose":62.09}},"requestUrl":"/m/hq/s/688076","defaultTab":"news","newsList":[{"id":"2461456157","title":"华福证券:给予诺泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461456157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461456157?lang=zh_cn&edition=full","pubTime":"2024-08-23 18:45","pubTimestamp":1724409920,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司盛丽华近期对诺泰生物进行研究并发布了研究报告《业绩表现亮眼,产能加速布局,拥抱趋势》,本报告对诺泰生物给出买入评级,当前股价为61.45元。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级11家,增持评级2家;过去90天内机构目标均价为84.25。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300038507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688076"],"gpt_icon":0},{"id":"2461550588","title":"最先从减肥药上赚到钱的中国公司出现了","url":"https://stock-news.laohu8.com/highlight/detail?id=2461550588","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461550588?lang=zh_cn&edition=full","pubTime":"2024-08-23 17:17","pubTimestamp":1724404646,"startTime":"0","endTime":"0","summary":"报告期内,公司延续了2023年的增长态势,营收、归母净利润、扣非净利润分别为8.31亿元、2.27亿元、2.29亿元,分别同比增长107.47%、442.77%、433.45%。而拉长时间先来看,公司6月公布本次业绩预期的近一年内,其股价涨幅超100%。其中,前者包括多肽原料药及制剂、小分子原料药及制剂,涉及糖尿病、心血管、肿瘤等疾病。而同期,以司美格鲁肽为代表的GLP-1降糖减重药物销量快速蹿升。这一势头延续至2024年上半年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082317180595b7a133&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082317180595b7a133&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2461551495","title":"国金证券:给予诺泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461551495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461551495?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:31","pubTimestamp":1724401884,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司赵海春,袁维近期对诺泰生物进行研究并发布了研究报告《多肽产能与订单齐升,1H24净利润7倍增长》,本报告对诺泰生物给出买入评级,当前股价为61.45元。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级11家,增持评级2家;过去90天内机构目标均价为84.25。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300028349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"gpt_icon":0},{"id":"2461436551","title":"信达证券:给予诺泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461436551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461436551?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:31","pubTimestamp":1724401884,"startTime":"0","endTime":"0","summary":"信达证券股份有限公司唐爱金,史慧颖近期对诺泰生物进行研究并发布了研究报告《业绩高增长,“时间+技术”领先优势逐步扩大》,本报告对诺泰生物给出买入评级,当前股价为61.45元。 诺泰生物 事件:诺泰生物发布2024年中报。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级11家,增持评级2家;过去90天内机构目标均价为84.25。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300028348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601059","688076"],"gpt_icon":0},{"id":"2461255571","title":"信达证券给予诺泰生物买入评级,业绩高增长,“时间+技术”领先优势逐步扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2461255571","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461255571?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:47","pubTimestamp":1724399220,"startTime":"0","endTime":"0","summary":"信达证券08月23日发布研报称,给予诺泰生物(688076.SH,最新价:61.45元)买入评级。评级理由主要包括:1)盈利能力大幅提升,研发投入拉升费用率;2)自主选择、定制类产品双轮驱动业绩高增长;3)保持“时间+技术”领先优势,原料药、制剂竞争力持续增强;4)产能有望快速增加,驱动公司未来发展。风险提示:行业竞争加剧、研发投入及外包需求下降、政策风险、新业务拓展不及预期等风险。AI点评:诺泰生物近一个月获得4份券商研报关注,买入3家。(文章来源:每日经济新闻)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315534995b73678&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315534995b73678&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601059","688076"],"gpt_icon":0},{"id":"2461558481","title":"诺泰生物08月23日主力资金流入1132万元 连续7日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2461558481","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461558481?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:18","pubTimestamp":1724397482,"startTime":"0","endTime":"0","summary":"08月23日, 诺泰生物股价跌1.03%,报收61.45元,成交金额2.81亿元,换手率2.08%,振幅6.75%,量比1.70。诺泰生物今日主力资金净流入1132万元,连续7日净流入,上一交易日主力净流入392万元,今日环比增加188.78%。该股近5个交易日下跌2.04%,主力资金累计净流入4473万元;近20日主力资金累计净流出2.18亿元,其中净流出天数为10日。该行业中净流入前三个股分别为诺泰生物、凯莱英、泰格医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315310895b71eaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315310895b71eaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2461532822","title":"诺泰生物(688076)双轮驱动高景气增长,2024H1业绩增长符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2461532822","media":"申万宏源","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461532822?lang=zh_cn&edition=full","pubTime":"2024-08-23 14:16","pubTimestamp":1724393805,"startTime":"0","endTime":"0","summary":"2024年中报发布,业绩增长符合预期。根据6月20日公司发布半年度业绩预告,预计2024H1实现归母利润1.8-2.5亿,半年度实际利润符合预告区间,业绩增长符合预期。双轮驱动实现高速增长,提升公司盈利能力。2024年公司上半年自主选择产品实现营业收入5.45亿元,同比增长119.76%;定制类产品及服务实现营业收入2.86亿元,同比增长88.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082314304495b6e35e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082314304495b6e35e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2461587798","title":"民生证券:给予诺泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461587798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461587798?lang=zh_cn&edition=full","pubTime":"2024-08-23 12:19","pubTimestamp":1724386789,"startTime":"0","endTime":"0","summary":"民生证券股份有限公司王班,乔波耀近期对诺泰生物进行研究并发布了研究报告《2024年半年报点评:新签多个全球重磅原料药项目,十吨级产能加速建设中》,本报告对诺泰生物给出买入评级,当前股价为60.38元。 诺泰生物 事件:2024年8月22日,诺泰生物发布2024年半年报。最新盈利预测明细如下:该股最近90天内共有11家机构给出评级,买入评级9家,增持评级2家;过去90天内机构目标均价为84.25。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300018115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688076"],"gpt_icon":0},{"id":"2461586003","title":"诺泰生物(688076):国际化BD持续发力 优质产能领先布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2461586003","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461586003?lang=zh_cn&edition=full","pubTime":"2024-08-23 11:04","pubTimestamp":1724382263,"startTime":"0","endTime":"0","summary":"发展趋势自主选择产品上量迅速,国际化BD 团队持续深化客户合作。定制类产品及服务收入2.86亿元,同比+88.16%,毛利率60.1%,处于领先水平。公司于2023 年5 月与欧洲某大型药企签约的合同总金额1.02 亿美元CDMO 长期供货合同已于2Q24 开始交付,公司预计2H24 将加快交付节奏。优质产能布局进度领先,建设有序推进。维持跑赢行业评级和88.00 元目标价,对应47.8 倍2024 年市盈率和34.6 倍2025 年市盈率,较当前股价有41.7%上行空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408231104319f4a4eab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408231104319f4a4eab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2461586807","title":"中泰证券给予诺泰生物买入评级,业绩超过预告中枢,多项战略合作落地,产能释放加速,持续高增有望延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2461586807","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461586807?lang=zh_cn&edition=full","pubTime":"2024-08-23 10:14","pubTimestamp":1724379297,"startTime":"0","endTime":"0","summary":"中泰证券08月22日发布研报称,给予诺泰生物买入评级。评级理由主要包括:1)业绩超过预告中枢,多肽领域优势持续兑现,持续高增态势有望延续;2)多肽、特色原料药为主的自主选择产品持续高速增长,小分子CDMO呈稳步恢复态势。AI点评:诺泰生物近一个月获得2份券商研报关注,买入1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408231029149f4a315d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408231029149f4a315d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","600918"],"gpt_icon":0},{"id":"2461000833","title":"民生证券给予诺泰生物推荐评级:新签多个全球重磅原料药项目,十吨级产能加速建设中","url":"https://stock-news.laohu8.com/highlight/detail?id=2461000833","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461000833?lang=zh_cn&edition=full","pubTime":"2024-08-23 09:34","pubTimestamp":1724376873,"startTime":"0","endTime":"0","summary":"民生证券08月23日发布研报称,给予诺泰生物(688076.SH,最新价:63.99元)推荐评级。评级理由主要包括:1)自主选择产品收入快速增长,全球订单BD拓展成果显著;2)规模化生产技术优势显著,十吨级多肽原料药产能加速建设中。风险提示:需求下降风险、技术创新风险、行业竞争加剧风险、生产风险、汇率风险等。文章来源:每日经济新闻原标题:民生证券给予诺泰生物推荐评级:新签多个全球重磅原料药项目,十吨级产能加速建设中","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408230949059f4a0a05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408230949059f4a0a05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","161027"],"gpt_icon":0},{"id":"2461304897","title":"诺泰生物:业绩高增,多肽原料药腾飞","url":"https://stock-news.laohu8.com/highlight/detail?id=2461304897","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461304897?lang=zh_cn&edition=full","pubTime":"2024-08-23 09:07","pubTimestamp":1724375265,"startTime":"0","endTime":"0","summary":"上半年, 诺泰生物 营业收入同比增长 107.47%,达 8.31 亿元,归母净利润同比增长 442.77%,达 2.27 亿元,基本每股收益上升至 1.06 元,同比增长 4.3 倍。在 GLP-1 明星药品带动下,多肽 原料药 采购需求增长,作为国内多肽原料药领军企业,诺泰生物自主选择产品实现营业收入 5.45 亿元,同比增长 119.76%,定制类业务营业收入 2.86 亿元,同比增长 88.16%。诺泰生物已建立长链 多肽药 物规模化生产的技术壁垒,司美格鲁肽等长链修饰多肽药物单批次产量超 10 公斤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082309093495b5e7ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082309093495b5e7ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688076"],"gpt_icon":0},{"id":"2461139399","title":"诺泰生物(688076.SH)发布半年度业绩 净利润2.27亿元 大涨442.77% 每10派1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461139399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461139399?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:05","pubTimestamp":1724321128,"startTime":"0","endTime":"0","summary":"智通财经APP讯,诺泰生物 披露2024年半年度报告,该公司报告期实现营业收入8.31亿元,同比增长107.47%。归属于上市公司股东的净利润2.27亿元,同比增长442.77%。报告期内,该公司自主选择产品及定制类产品销售收入同比均有较大增长,使得营业收入实现快速增长。此外,净利润较上年同期增长442.77%,主要因营业收入同比增长;高毛利率的产品在收入结构中占比持续提升;随着营收规模扩大,规模效应逐渐形成,带动报告期整体毛利率有所提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688076"],"gpt_icon":0},{"id":"2461399046","title":"诺泰生物:2024年上半年净利润2.27亿 同比增长442.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461399046","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461399046?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:25","pubTimestamp":1724318700,"startTime":"0","endTime":"0","summary":"诺泰生物公告,公司2024年上半年实现营业收入8.32亿,同比增长107.47%;净利润2.27亿,同比增长442.77%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221727169f4768db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221727169f4768db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076"],"gpt_icon":0},{"id":"2461132038","title":"诺泰生物08月21日主力资金流入399万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2461132038","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461132038?lang=zh_cn&edition=full","pubTime":"2024-08-21 15:18","pubTimestamp":1724224739,"startTime":"0","endTime":"0","summary":"08月21日, 诺泰生物股价跌1.21%,报收62.09元,成交金额1.77亿元,换手率1.30%,振幅4.01%,量比1.10。诺泰生物今日主力资金净流入399万元,连续5日净流入,上一交易日主力净流入1140万元,今日环比减少65.00%。该股近5个交易日上涨3.16%,主力资金累计净流入4810万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流出2.31亿元,其中净流出天数为11日。该行业中净流入前三个股分别为诺泰生物、昭衍新药、阳光诺和。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082115343895ad9ef6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082115343895ad9ef6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2461865838","title":"医疗服务行业盘中拉升,诺泰生物涨1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461865838","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461865838?lang=zh_cn&edition=full","pubTime":"2024-08-21 09:40","pubTimestamp":1724204420,"startTime":"0","endTime":"0","summary":"08月21日,医疗服务行业盘中拉升,截至09点40分,医疗服务行业整体指数上涨0.53%,报3944.130点。从个股上来看,该行业的成分股中,诺泰生物涨1.03%,ST中珠、成都先导、诺禾致源涨幅居前。从资金上来看,截止发稿,医疗服务行业主力净流入为-3087.16万,其中昭衍新药受到资金热捧,主力净流入324.24万;拉长时间线来看,该板块近20日主力资金净流入-33.83亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082109402096826e73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082109402096826e73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688076"],"gpt_icon":0},{"id":"2460013663","title":"医疗服务行业盘中拉升,诺泰生物涨1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460013663","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460013663?lang=zh_cn&edition=full","pubTime":"2024-08-20 09:39","pubTimestamp":1724117965,"startTime":"0","endTime":"0","summary":"08月20日,医疗服务行业盘中拉升,截至09点39分,医疗服务行业整体指数上涨0.53%,报4030.240点。从个股上来看,该行业的成分股中,诺泰生物涨1.11%,ST中珠、新里程、贝瑞基因涨幅居前。从资金上来看,截止发稿,医疗服务行业主力净流入为-4727.96万,其中博腾股份受到资金热捧,主力净流入249.74万;拉长时间线来看,该板块近20日主力资金净流入-34.59亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820093925af977e5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820093925af977e5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688076"],"gpt_icon":0},{"id":"2460709896","title":"诺泰生物08月19日主力资金流入1406万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2460709896","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460709896?lang=zh_cn&edition=full","pubTime":"2024-08-19 15:18","pubTimestamp":1724051916,"startTime":"0","endTime":"0","summary":"08月19日, 诺泰生物股价涨0.27%,报收62.90元,成交金额1.64亿元,换手率1.20%,振幅3.01%,量比0.93。诺泰生物今日主力资金净流入1406万元,连续3日净流入,上一交易日主力净流入1630万元,今日环比减少13.74%。该股近5个交易日上涨3.81%,主力资金累计净流入1811万元;近20日主力资金累计净流出2.98亿元,其中净流出天数为13日。该行业中净流入前三个股分别为诺泰生物、康龙化成、皓元医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081915302595a5f84d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081915302595a5f84d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688076"],"gpt_icon":0},{"id":"2460276408","title":"诺泰生物(688076)8月16日主力资金净买入1717.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460276408","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460276408?lang=zh_cn&edition=full","pubTime":"2024-08-17 08:13","pubTimestamp":1723853589,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月16日收盘,诺泰生物报收于62.73元,上涨2.33%,换手率1.46%,成交量3.18万手,成交额1.99亿元。近5日资金流向一览见下表:诺泰生物融资融券信息显示,融资方面,当日融资买入933.72万元,融资偿还627.02万元,融资净买入306.7万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081700012851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2459641012","title":"诺泰生物(688076.SH)通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2459641012","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459641012?lang=zh_cn&edition=full","pubTime":"2024-08-16 16:09","pubTimestamp":1723795798,"startTime":"0","endTime":"0","summary":"智通财经APP讯,诺泰生物(688076.SH)公告,公司于近日收到江苏省药品监督管理局签发的《出口欧盟原料药证明文件》(编号:JS240048)、《药品GMP符合性检查告知书》(苏药监药生告知[2024]231号、232号),公司连云港工厂的106车间原料药(利拉鲁肽,仅用于出口欧盟文件办理)生产线、106车间原料药(依替巴肽)生产线、101车间原料药(醋酸西曲瑞克)生产线经江苏省药品监督管理局的现场检查,符合《药品生产质量管理规范》要求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688076"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-05-20","address":"江苏省连云港市连云区经济技术开发区临浦路28号","stockEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0621},{"period":"3month","weight":0.0934},{"period":"6month","weight":0.305},{"period":"1year","weight":1.153},{"period":"ytd","weight":0.3761}],"companyName":"江苏诺泰澳赛诺生物制药股份有限公司","boardCode":"AI0027","perCapita":"18532股","boardName":"医药制造业","registeredCapital":"21977万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 江苏诺泰澳赛诺生物制药股份有限公司是一家聚焦多肽药物及小分子化药进行自主研发与定制研发生产相结合的生物医药企业。公司的主要产品为阿托伐他汀钙片、氨氯地平阿托伐他汀钙片、利拉鲁肽、司美格鲁肽、苯甲酸阿格列汀、比伐芦定、依替巴肽、醋酸兰瑞肽、醋酸奥曲肽、磷酸奥司他韦、胸腺法新、GLP-1/GIP/GCG受体多靶点激动剂1类新药、氟维司群。","serverTime":1724567184888,"listedPrice":15.57,"stockholders":"11859人(较上一季度增加18.90%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺泰生物(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺泰生物(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺泰生物,688076,诺泰生物股票,诺泰生物股票老虎,诺泰生物股票老虎国际,诺泰生物行情,诺泰生物股票行情,诺泰生物股价,诺泰生物股市,诺泰生物股票价格,诺泰生物股票交易,诺泰生物股票购买,诺泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺泰生物(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺泰生物(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}